ReviewFrontiers in endocrinology2026
Beta-cell replacement for type 1 diabetes: integrating cell products, engraftment and immune protection.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-cell replacement aims to restore endogenous, glucose-responsive insulin secretion in type 1 diabetes. Donor-islet transplantation has shown that this approach can improve glycaemic control and prevent severe hypoglycaemia. Its wider use is limited by donor supply, early graft loss and chronic systemic immunosuppression. Pluripotent stem cells provide a renewable source of pancreatic progenitors and differentiated islet products. Recent clinical studies have reported C-peptide secretion and insulin independence in some recipients. However, cell supply is only one part of the problem. Product maturity, graft composition, implantation site, vascular support, immune injury and manufacturing quality all affect outcome. This review examines these factors as parts of one treatment system. It compares donor islets, stem-cell-derived products and islet-like organoids, then evaluates delivery and immune-protection strategies. It also considers clinical endpoints, patient selection and safety. We define functional cure as durable endogenous insulin secretion with physiological benefit at an acceptable total treatment burden. Current evidence provides early evidence of clinical activity and, in selected recipients, clinically meaningful efficacy. However, the available studies involve highly selected participants, small cohorts and/or systemic immunosuppression. No platform has yet combined durable function, immune control, scalable production and acceptable long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.